RE-BVS – Piemonte Repository

Sfoglia per AUTORE
TANI M
Collezione AO Cuneo

Items : 6

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara

Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study. in Cancers / Cancers (Basel). 2022 Jan 27;14(3):654. doi: 10.3390/cancers14030654.

2022
AO Cuneo
AOU Novara

Petrini M; Stefoni V; Zinzani PL; Tisi MC; Kovalchuk S; Tani M; Pozzi S; Musuraca G; Rosignoli C; Arcari A; D'Alò F; Luzi D; Cantonetti M; Pane F; Gini G; Cuneo A; Visco C; Margiotta Casaluci G; Stefani PM; Casadei B; Patti C; Broccoli A; Argnani L;

How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. in Leukemia & lymphoma / Leuk Lymphoma. 2022 Aug;63(8):1985-1988. doi: 10.1080/10428194.2022.2053532. Epub 2022 Mar 27.

2022
AO Cuneo
AOU Città della Salute di Torino

Tedeschi A; Ferrario A; Montillo M; Zamprogna G; Marinoni S; Tani M; Ferrarini I; Borella C; Varettoni M; Ibatici A; Motta M; Sanna A; Massaia M; Orsucci L; Quaresmini G; Vanazzi A; Vitale C; Reda G; Mauro FR; Laurenti L; Murru R; Visentin A; Frustaci AM; Sportoletti P; Deodato M;

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. in The oncologist / Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

2019
ASL Biella
AO Cuneo
AOU Città della Salute di Torino

Zinzani PL; Castellino C; Gaudio F; Argnani L; Zancanella M; Paolini R; Rigacci L; Devizzi L; Monaco F; Romano A; Fama A; Patti C; Musuraca G; Tecchio C; Marino D; Goldaniga MC; Marasca R; Cox MC; Cascavilla N; Conconi A; Balzarotti M; Tani M; Broccoli A; Casadei B; Chiappella A; Visco C;

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience. in Clinical lymphoma, myeloma & leukemia / Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar

2019
AO Cuneo
AOU Città della Salute di Torino

Argnani L; Gaudio F; Castellino C; Rigacci L; Rusconi C; Romano A; Monaco F; Devizzi L; Tecchio C; Marasca R; Cox MC; Tani M; Zinzani PL; Visco C; Castellino A; Marangon M; Stefoni V;